GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS TO REACH $47.1 BILLION IN 2017 Wellesley, Mass.

According to a new technical market research report, GLOBAL MARKETS FOR ASTHMA AND COPD DRUGS (PHM059B) from BCC Research (www.bccresearch.com), the global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011.This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%. The market for asthma and COPD drugs can be split into three segments by disease: asthma drugs, COPD drugs, and combinations of the two drugs. The segment made up of asthma drugs is projected to increase from $15.3 billion in 2012 to $20.2 billion in 2017, a CAGR of 5.7%. COPD drugs are expected to increase from $5.3 billion in 2012 to $5.6 billion in 2017, a CAGR of 1.2%. Combination drugs are expected to be worth $17.4 billion in 2012 and should reach $21.3 billion in 2017, a CAGR of 4.1%. Asthma and COPD are two diseases experiencing increasing prevalence globally due to a combination of factors, including a globally aging population and increasing pollution levels. COPD is one of the top five causes of disability and death in industrialized countries and the fourth-leading cause of death globally. The market for asthma and COPD drugs had global revenues in 2010 that exceeded $34 billion annually. These drugs enjoy tremendous commercial success, as illustrated by the presence of six currently marketed multibillion-dollar drugs in this market. A perceived high level of unmet need in this market exists, however, in terms of treatment options for asthma and COPD patients. With the loss of patent protection on several major COPD and asthma drugs between 2010 and 2017, the cost for some treatments is expected to decrease as generic versions gain market share. Additionally, several new drugs are projected to enter the market through 2017, and they will continue to drive growth of revenues for asthma and COPD drugs. This report will help its audience:

Analyze industry structure as well as competition within, including tiers of competition, regulatory aspects, and competitive factors

Assess market needs, challenges, and trends Forecast overall market revenue and current market shares, as well as forecast by major drug class, disease indication, and geographical region Review and analyze compounds in clinical trials with an emphasis on drugs in advanced stages of development.

This report provides information that is useful for business planners, market researchers, marketers, business developers, investors, venture capitalists, consultants, and anyone who wants to understand or invest in this market. The information is also useful for technology-licensing and scientific research-and-development purposes. SUMMARY FIGURE GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY REGION, 2012 AND 2017 (%)

Source: BCC Research Global Markets for Asthma and COPD Drugs (PHM059B)

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: editor@bccresearch.com as the source and publisher, along with report number, which can be found in the first paragraph of this release.